Trials / Completed
CompletedNCT00147589
A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.
Peds I (Pediatric Eplerenone Development Study I): A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of Eplerenone In The Treatment Of Hypertension In Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 320 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 6 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eplerenone |
Timeline
- Start date
- 2004-09-01
- Completion
- 2007-01-01
- First posted
- 2005-09-07
- Last updated
- 2020-12-22
Locations
41 sites across 5 countries: United States, Dominican Republic, India, Russia, South Africa
Source: ClinicalTrials.gov record NCT00147589. Inclusion in this directory is not an endorsement.